IV Therapy Clinic EBITDA Multiples: 2.5x–5.5x — What Buyers Pay (2026)
Cash-pay IV hydration clinics trade at 3x–5.5x EBITDA. Here's exactly what moves the needle up or down for buyers and sellers in this fragmented wellness sector.
IV therapy clinics typically sell at 3.0x–5.5x EBITDA in the lower middle market. Valuations hinge on recurring membership revenue, transferable medical director agreements, and regulatory compliance. Clinics generating $500K+ EBITDA with documented clinical protocols, 200+ active members, and multi-location footprints command premium multiples from med spa rollup buyers and SBA-financed entrepreneurs.
IV Therapy Clinic EBITDA Multiples (2026)
| Practice Size | EBITDA Range | Multiple Range | Notes |
|---|---|---|---|
| Distressed or Single-Location Operator | $150K–$300K | 2.5x–3.0x | Walk-in revenue only, owner serves as medical director, no membership program, limited documentation, and unresolved compliance gaps discount value significantly. |
| Established Single-Location Clinic | $300K–$500K | 3.0x–4.0x | Decent membership base, transferable medical director agreement, 2+ years of clean financials, and stable staff qualify for SBA 7(a) financing at this tier. |
| Growth-Stage Multi-Service Clinic | $500K–$750K | 4.0x–5.0x | 200+ active members, diversified services including NAD+ and peptides, strong Google reputation, and a replaceable medical director attract PE-backed rollup interest. |
| Premium Multi-Location Platform | $750K–$2M+ | 5.0x–5.5x | Two or more locations, proven membership retention above 70%, mobile IV unit, documented SOPs, and physician partnerships support top-of-market strategic pricing. |
Valuation Drivers — What Makes Your Multiple Higher or Lower
The spread between 3.5x and 6.5x is not random. These seven factors determine where your firm lands.
Membership Revenue Quality
High PositiveActive monthly memberships with documented retention and churn data provide predictable cash flow that buyers pay a premium for, often justifying a full multiple turn higher than walk-in-only clinics.
Medical Director Agreement Transferability
High PositiveA physician willing to remain post-close under a transferable, state-compliant medical director agreement is a prerequisite for SBA financing and removes the single biggest regulatory risk buyers fear.
Owner Dependency Risk
High NegativeWhen the owner is the sole medical director or primary clinical staff, buyers discount heavily or require extended earnouts to offset the operational collapse risk following transition.
Regulatory and Compliance Documentation
Moderate PositiveCurrent state health department permits, documented clinical protocols, nurse licensure files, and compliant compounding pharmacy agreements materially reduce buyer due diligence risk and support higher pricing.
Service Menu Diversification
Moderate PositiveClinics offering NAD+ infusions, peptide injections, and weight management programs alongside hydration therapy generate higher revenue per visit and attract a broader recurring client base.
Recent Market Trends
PE-backed med spa rollup platforms accelerated IV therapy clinic acquisitions in 2023–2024, compressing deal timelines and pushing premium multiples toward 5.5x for membership-driven operators. Simultaneously, FDA scrutiny of compounded infusion products and tightening state regulations around nurse-only administration have increased buyer due diligence intensity, creating a wider valuation gap between compliant and non-compliant sellers.
Who Buys IV Therapy Clinics in 2026
Individual Operator / Search Fund
Entrepreneurship through acquisition (ETA), first-time buyers, industry-adjacent operators
What they want: Stable, transferable cash flow in a IV Therapy Clinic. SBA-eligible business, strong membership revenue quality, and a seller available for a 12–18 month transition.
Pros for seller
- +SBA 7(a) financing means 10% buyer equity — faster than waiting for institutional capital
- +Buyer works inside the business, maintaining client and staff relationships
- +Deal structure is typically straightforward: cash at close plus seller note
Cons for seller
- −Lower multiples than PE buyers — typically at the low-to-mid end of the range
- −Requires meaningful seller involvement post-close for transition
- −SBA approval timeline adds 60–90 days to closing
PE-Backed Roll-Up Platform
Private equity consolidators building a IV Therapy Clinic portfolio, regional or national platforms
What they want: Scale, operational quality, and geographic coverage. Strong membership revenue quality with minimal owner dependency risk. Clean financials, documented systems, and staff who can operate without the selling owner.
Pros for seller
- +All-cash close with no SBA financing contingency or approval delay
- +Highest multiples available for premium businesses
- +Equity rollover option — seller keeps 10–30% stake and participates in platform exit
Cons for seller
- −Extensive 90–150 day due diligence process
- −Post-close integration into a larger platform changes operating culture
- −Usually requires seller to remain in a leadership role for 12–24 months
Strategic Acquirer
Larger IV Therapy Clinic operators, adjacent-industry buyers adding capacity or geography
What they want: Client relationships, staff, and market position that complement existing operations. Membership Revenue Quality is especially valuable when it fills a gap the buyer cannot build organically.
Pros for seller
- +Can pay above-model multiples for strong strategic fit
- +Buyer already understands the business — diligence moves faster
- +Shorter transition requirement when operational overlap exists
Cons for seller
- −Fewer competing buyers — less negotiating leverage
- −Non-compete scope is typically broader than PE or individual deals
- −Operations and brand may change significantly post-close
Sample IV Therapy Clinic Transactions
Single-location IV therapy clinic in a suburban wellness market with 180 active members, transferable medical director agreement, and two years of CPA-reviewed financials. No prior regulatory issues.
$420K
EBITDA
3.8x
Multiple
$1.6M
Price
Two-location cash-pay hydration clinic with NAD+ and peptide services, 310 active members, 72% monthly retention, and a physician retained post-close. SBA 7(a) financed with 15% seller note.
$680K
EBITDA
4.7x
Multiple
$3.2M
Price
Three-location IV therapy platform with mobile unit, documented SOPs, gym referral partnerships, and 4.9-star Google reputation. Acquired by regional med spa rollup as anchor asset.
$1.1M
EBITDA
5.2x
Multiple
$5.7M
Price
EBITDA Valuation Estimator
Get your IV Therapy Clinic business value range instantly
Industry: IV Therapy Clinic · Multiples based on 3.0x–4.0x (Established Single-Location Clinic)
Powered by DealFlow OS
dealflow-os.com · Free M&A tools for every stage of the deal
How to Use These Multiples
For Sellers: 4-Step Valuation Walkthrough
- 1
Compile three years of P&L statements and tax returns that reconcile line by line — SBA lenders and institutional buyers both require this, and any unexplained gap triggers diligence delays or price renegotiation.
- 2
Build a normalized EBITDA schedule with every add-back documented: owner W-2 above a market-rate manager salary, personal expenses, one-time items, and non-recurring costs. Undocumented add-backs get cut.
- 3
Address your owner dependency risk before going to market — this is the most common reason IV Therapy Clinic businesses receive offers at the low end of the 2.5x–5.5x range. Buyers identify it in diligence and reprice accordingly.
- 4
Quantify and document your membership revenue quality with supporting records: contracts, renewal histories, and client revenue breakdowns. This is the primary evidence for commanding a premium multiple — have it ready before the first buyer call.
For Buyers: Validate the Asking Multiple
- 1
Request trailing 12-month and 3-year P&L with bank statement backup before making an offer. If a IV Therapy Clinic seller cannot produce reconciled financials, that signals what the full diligence process will look like.
- 2
Verify the membership revenue quality claims independently — pull contract copies, renewal documentation, and client-level revenue data. This is the primary driver of whether this IV Therapy Clinic is worth 5.5x or 2.5x.
- 3
Assess owner dependency risk directly: ask which revenue or client relationships depend on the current owner personally, and what the transition plan is. An exit-ready seller has already worked through this.
- 4
Model your SBA debt service against verified EBITDA before signing the LOI. At current rates, a $1M SBA 7(a) loan runs approximately $13,000/month over 10 years — the business needs at least 1.25x debt service coverage after a market-rate manager salary.
Frequently Asked Questions
What EBITDA multiple should I expect when selling my IV therapy clinic?
Most IV therapy clinics sell at 3.0x–5.5x EBITDA. Clinics with transferable medical director agreements, active membership programs, and multi-location footprints command the highest multiples from strategic and PE buyers.
Do IV therapy clinics qualify for SBA financing?
Yes. IV therapy clinics are SBA 7(a) eligible as cash-pay healthcare businesses. Buyers typically finance 75–90% of the purchase price with SBA loans, often paired with a seller note or earnout covering the balance.
What is the biggest factor that reduces an IV therapy clinic's valuation?
Owner dependency as the sole medical director is the top value killer. Without a replacement physician and a transferable medical director agreement, most buyers will not proceed or will demand deep price discounts.
How long does it take to sell an IV therapy clinic?
Expect 12–18 months from exit planning to close. Sellers who document financials, formalize clinical protocols, and recruit a replacement medical director at least 12 months before listing achieve significantly better outcomes and multiples.
More IV Therapy Clinic Guides
Related Reading
Find IV Therapy Clinic businesses at the right price
DealFlow OS surfaces acquisition targets with seller signals and outreach angles. Free to join.
No credit card required